塞来昔布治疗急性偏头痛的临床观察  

Clinical Observation on Celecoxib in The Treatment of Acute Migraine

作　　者：张君雁 ZHANG Jun-yan(Department of Neurology,The Affiliated Hospital of Xinyang Vocational and Technical College,Xinyang 464000,Henan Province,China)

机构地区：[1]信阳职业技术学院附属医院神经内科,河南信阳464000

出　　处：《罕少疾病杂志》2023年第6期15-16,共2页Journal of Rare and Uncommon Diseases

摘　　要：目的 观察塞来昔布治疗偏头痛的临床效果。方法 研究对象为在本院诊治的120例急性偏头疼患者,随机分为对照组(n=60,给予苯甲酸利扎曲普坦片治疗)和观察组(n=60,给予塞来昔布+苯甲酸利扎曲普坦片治疗),连续治疗2周,对两组的治疗效果和安全性进行评价。结果 两组2h头痛缓解率和2h最烦人症状缓解率比较,观察组均高于对照组(P<0.05)。治疗后,观察组视觉模拟评分(VAS)显著低于对照组(P<0.05),改善值高于对照组(P<0.05)。治疗后,观察组头痛发作频率及维持时间均少于对照组(P<0.05)。治疗期间,两组均未出现心血管不良事件,且两组不良反应发生率比较,差异无统计需意义(P>0.05)。结论 在治疗急性偏头痛时加用塞来昔布可以提高临床疗效,而且安全较高。Objective To observe the clinical effect of celecoxib in the treatment of migraine.Methods Totally 120 patients with acute migraine who were diagnosed and treated in the hospital were selected as the subjects of the study,and they were randomly divided into control group(n=60,treated with rizatriptan benzoate tablets)and observation group(n=60,given celecoxib+rizatriptan benzoate tablets),and the two groups were continuously treated for 2 weeks.The therapeutic effect and safety of the two groups were evaluated.Results The 2h headache relief rate and 2h most annoying symptom relief rate of observation group were higher than those of control group(P<0.05).After treatment,the Visual Analogue Score(VAS)of observation group was significantly lower than that of control group(P<0.05),and the improvement value was higher than that of control group(P<0.05).After treatment,the frequency and duration of headache attack in observation group were less or shorter than those in control group(P<0.05).During treatment,there were no cardiovascular adverse events in the two groups,and there were no statistically significant differences in the incidence rates of adverse reactions between the two groups(P>0.05).Conclusion Addition of celecoxib can improve the clinical efficacy and has a high safety in the treatment of acute migraine.

关 键 词：急性偏头痛 塞来昔布 治疗效果 安全性 

分 类 号：R747.2[医药卫生—神经病学与精神病学]